Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: Provided herein are combinations or compositions comprising immunomodulators and immune cell engaging proteins. Also provided herein are methods of use thereof, such as methods of treatment by administering the combinations or compositions comprising immunomodulators and immune cell engaging proteins to a subject. The method may be used to treat a cancer in the subject.

Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.

Abstract: Provided herein are EpCAM binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EpCAM binding proteins. Also disclosed are methods of using the disclosed EpCAM binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.

Abstract: Disclosed herein are conditionally active receptors which comprise a target antigen binding domain and a binding moiety. Each binding moiety comprises non-CDR loops for masking the binding of a target antigen binding domain to its target. The receptors are activated upon cleavage of the cleavable linkers. Pharmaceutical compositions comprising cells comprising the conditionally active receptors disclosed herein and methods of using such formulations are further provided.

Abstract: Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.

Abstract: Disclosed herein are conditionally active multivalent target-binding proteins which comprise two binding moieties, two linkers, two target antigen binding domains, and a constant domain. Each binding moiety comprises non-CDR loops for masking the binding of a target antigen binding domain to its target and CDRs for binding a further target. The multivalent target-binding proteins are activated upon cleavage of the cleavable linkers. Also disclosed are pro immune modulating molecules comprising dual binding moieties comprising non-CDR loops and cleavable linkers, that prohibit the binding of a target binding domain to their targets (e.g., binding of an antibody to an immune modulatory target is masked by the dual binding moieties). The dual binding moieties further have specificity for a bulk serum protein or a dual binding moiety target (e.g., a tumor antigen, an immune modulatory protein).

Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Disclosed herein are binding moieties that comprise non-CDR loops for masking the binding of a binding molecule to its target and CDRs for binding bulk serum proteins. Conditionally active target binding proteins that contain the binding moieties are also provided. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: Disclosed herein is a dual binding moiety that comprises non-CDR loops for masking the binding of a domain, such as a target antigen binding domain to its target, by steric occlusion and specific masking, and CDRs for binding bulk serum proteins. Pharmaceutical compositions comprising the dual binding moiety disclosed herein and methods of using such compositions are further provided.

Abstract: Disclosed herein is a conditionally active target binding protein that contains a first binding domain that binds to a bulk serum protein and sterically occludes binding of a second binding domain to its target. Pharmaceutical compositions comprising the conditionally active binding proteins disclosed herein and methods of using such compositions are further provided.

Abstract: Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.